RNA-targeted aminopyridine compounds provide a new antifungal strategy

Researchers have discovered that aminopyridine compounds targeting RNA could revolutionize antifungal therapy. Traditionally, finding suitable RNA targets for drug development has been challenging due to the lack of well-defined binding sites. However, a group I intron, a self-splicing ribozyme found in fungal mitochondria but not in human cells, presents an attractive alternative.

By recalibrating an intron-splicing assay to mimic cellular conditions, scientists were able to conduct a comprehensive structure-activity relationship study on the Candida albicans group I intron. The research revealed that ligands with a flexible diamine structure were more effective than those with constrained conformations. This led to the development of lead compound 56, which demonstrated an impressive IC 21.6 nM activity.

What's more, compound 56 showed synergy with amphotericin B, a commonly used antifungal agent, against Candida albicans. The findings were confirmed through RT-qPCR, which demonstrated direct engagement of the fungal group I intron by the compound. This breakthrough not only establishes the fungal group I intron as a viable, mechanistically distinct antifungal target but also provides a promising model platform for future RNA-targeted drug discovery efforts.